Acrivon Therapeutics, Inc. Logo

Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):
US0048901096
LEI:
Country:
United States of America
Address:
480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea 476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openedges Technology, Inc. Logo
Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.
South Korea 394280
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710

Talk to a Data Expert

Have a question? We'll get back to you promptly.